Join
Live feed
·
PRReleasevia Quantisnow
BioLineRx Ltd. logo

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

ByQuantisnow·Wall Street's wire, on your screen.
BLRX· BioLineRx Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLRX (BioLineRx Ltd.) and more on Quantisnow.